ASARINA PHARMA AB (publ) ANNUAL REPORT 2021 RELEASED
Peter Nordkild, CEO: “Despite the challenges of the last year we remain committed to our goal of providing new effective therapy to patients with various neurological disorders. Topline data for our phase IIa study in Tourette are still expected in Q1 of 2023 and the study remains fully funded. We maintain our full focus on Sepranolone’s potential and move forward with focus and optimism.”FINANCIAL HIGHLIGHTS · Total operating costs were reduced by more than 50% to SEK 38.3 million. · R&D costs dropped to SEK 29.9 millionfrom SEK 63.7 million in 2020.The Company received a